Table 1 Individual patient information on demographics, histology, gene, and outcomes.
From: Pleomorphic xanthoastrocytomas of adults: MRI features, molecular markers, and clinical outcomes
Variable | Number (n = 50) |
|---|---|
Median age (years) | 36 (18–67) |
Gender | |
Male | 31 (62%) |
Female | 19 (38%) |
Symptoms | |
Seizures | 15 (30%) |
Headaches | 24 (48%) |
Focal neurological deficits | 13 (26%) |
Visual disturbances | 11 (22%) |
Extent of surgery | |
Gross total resection | 37 (74%) |
Subtotal resection | 10 (20%) |
Partial resection | 3 (6%) |
Histopathology | |
Grade II PXA | 26 (52%) |
Grade III anaplastic PXA | 24 (48%) |
BRAF V600E status | |
Mutated | 12 (41%) |
Non-V600E mutated | 17 (59%) |
N/A | 21 |
IDH1 status | |
Mutated | 1 (3%) |
Non-mutated | 35 (97%) |
N/A | 14 |
IDH2 status | |
Mutated | 0 |
Non-mutated | 36 (100%) |
N/A | 14 |
Clinical outcomes | |
Complete remission | 16 (53%) |
Recurrence or progression | 14 (47%) |
N/A | 20 |
